3810-10-4

Usage

Chemical Properties

White Solid

InChI:InChI=1/C12H10N2O/c13-12-10(7-4-8-14-12)11(15)9-5-2-1-3-6-9/h1-8H,(H2,13,14)

Upstream product

• 74959-42-5 2-Benzoylacetamidine 
• 125072-37-9 cis-3-ethoxyacrolein diethylacetal 
• 109-09-1 2-chloropyridine 
• 24517-64-4 2-amino-3-pyridinecarbonitrile 
• 100-58-3 phenylmagnesium bromide 
• 504-29-0 2-aminopyridine 
• 98-80-6 phenylboronic acid 
• 873-55-2 sodium benzenesulfonate 
• 1360114-38-0 C₁₄H₁₁BrN₂O₂ 
• 6919-61-5 N-methoxy-N-methylbenzamide 
• 86847-59-8 2-(pivaloylamino)pyridine 
• 100-52-7 benzaldehyde 
• 79574-62-2 2-fluoro-3-(phenyl-1-hydroxymethyl)pyridine 
• 372-48-5 2-fluoropyridine 

Downstream Products

• 125867-44-9 5-phenyl-6,7,8,9-tetrahydrobenzo<1,8>naphthiridine 
• 28721-30-4 4-phenyl-1,2-dihydropyrido<2,3-d>-2-pyrimidinone 
• 103409-25-2 2-amino-4-phenyl-1,8-naphthyridine-3-carbonitrile 
• 103409-24-1 3-cyano-2-hydroxy-4-phenyl-1,8-naphthyridine 
• 128175-04-2 5,11-diphenyldipyrido<2,3-b:2',3'-f><1,5>diazocine 
• 130277-16-6 2-amino-3-benzylpyridine 
• 167754-45-2 N-(3-benzoylpyridin-2-yl)-2,2,2-trichloroacetamide 
• 167754-46-3 3-[2-(diethylamino)ethyl]-4-phenyl-4-(trichloromethyl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one 
• 835882-03-6 (2-amino-5-bromo-pyridin-3-yl)-phenyl-methanone 
• 103409-26-3 2-amino-4-phenyl-1,8-naphthyridine-3-carboxamide 

Relevant academic research and scientific papers

Enantioselective Intramolecular Copper-Catalyzed Borylacylation

An enantioselective copper-catalyzed intramolecular borylacylation is reported. The reaction proceeds through an initial enantioselective borylcupration of the styrene, followed by a nucleophilic attack on the tethered carbamoyl chloride. The products, chiral borylated 3,3-disubstituted oxindoles, were generated in excellent yields and enantioselectivities. The versatile carbon–boron bond provides a platform for a wide array of diversification.

PROTEIN KINASE INHIBITORS

The present invention provides a compound incorporating a group of formula (I) wherein: 1 of X, Y and Z is nitrogen and the other 2 are carbon; V is sulpur or carbon; R3 is oxygen or fluorine; R4 is an optionally present C1-3 alkyl group optionally substituted by fluorine; R5 is an optionally present cyclic group with 5-7 heavy atoms in the ring which may be carbocyclic or heterocyclic and aromatic or aliphatic and is optionally substituted, e.g. by a halogen, C1-2 alkyl or fluoroalkyl, OH, OR6, cyano, COOR6, CONHR6, sulfonamide or NHR6, in which R6 is a C1-2 alkyl or fluoroalkyl; at least one of R4 and R5 is present and R4 and R5 may both be present; m and n are each 1 or 2 depending on the identity of V and R3; when n=2 each R3 may be the same or different but are preferably the same, when m=2, each R4 and each R5 may be the same or different but are preferably the same; and W represents hydrogen, carbon, nitrogen, oxygen or sulphur; or incorporating a salt, hydrate or solvate of a group of formula (I); as well as therapeutic uses of these compounds, in particular as inhibitors of protein kinase activity and in the treatment of inflammation, inflammatory conditions and cancer.

Palladium-catalyzed direct addition of arylboronic acids to 2-aminobenzonitrile derivatives: Synthesis, biological evaluation and in silico analysis of 2-aminobenzophenones, 7-benzoyl-2-oxoindolines, and 7-benzoylindoles

A palladium-catalyzed direct addition of arylboronic acids to unprotected 2-aminobenzonitriles has been developed, leading to a wide range of 2-aminobenzophenones with moderate to excellent yields. The transformation has broad scope and high functional group tolerance. Moreover, 2-oxoindoline-7-carbonitrile and indole-7-carbonitrile were applicable to this process for the construction of 7-benzoyl-2-oxoindolines and 7-benzoylindoles, respectively. Among the compounds examined, compound 4e possessed the most potent anticancer activity against H446 and HGC-27 in vitro, with IC50 values of 0.02 μmol L-1 and 0.09 μmol L-1, respectively, while compound 4a showed the best potent anticancer activity against SGC-7901 with an IC50 value of 0.01 μmol L-1. Furthermore, we also performed in silico molecular docking calculations to investigate the interaction mode and binding affinity between the examined compounds and their tubulin target. This journal is

Palladium-catalyzed direct addition of 2-Aminobenzonitriles to sodium arylsulfinates: Synthesis of o-Aminobenzophenones

The first example of the palladium-catalyzed synthesis of o-Aminobenzophenones in moderate to excellent yields via a direct addition of sodium arylsulfinates to unprotected 2-Aminobenzonitriles was reported. A plausible mechanism for the formation of o-Aminobenzophenones involving desulfination and addition reactions was proposed. The utility of this transformation was demonstrated by its compatibility with a wide range of functional groups. Thus, the method represents a convenient and practical strategy for synthesis of o-Aminobenzophenones.

Novel access to 1,4-benzodiazepin-2-ones via the Buchwald reaction and application to the synthesis of novel heterocyclics

A new two step strategy for the preparation of 1,4-benzodiazepin-2-ones has been developed starting from the 2-halogenobenzophenone under Buchwald conditions (Pd(OAc)2, XantPhos, Cs2CO3, dioxane 100 °C). This strategy has

Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): Pyridodiazepine amines

An SAR study of an HTS screening hit generated a series of pyridodiazepine amines as potent inhibitors of Helicobacter pylori glutamate racemase (MurI) showing highly selective anti-H. pylori activity, marked improved solubility, and reduced plasma protei

Synthesis of aza analogues of the anticancer agent batracylin

Three series of pyrido-fused pyrimido[2,1-a]isoindol-7-ones were prepared from readily available (aminopyridinyl)(aryl)methanones by reduction followed by a Mitsunobu reaction with phthalimide and acid-catalysed cyclodehydration. This approach provides a wide variety of aza analogues of the antitumour agent batracylin.

QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formulae I and II: (I) (II) wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Synthesis and structure-activity relationship studies on a novel series of naphthylidinoylureas as inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT)

The synthesis and structure-activity relationships of N-phenyl-N′-[3- (4-phenylnaphthylidinoyl)]urea derivatives 3 as a novel structural class of potent ACAT inhibitors is described. A 3-methoxy group substituted on the naphthylidinone 4-phenyl ring, toge